ArticleFrontiers in physiology2025
Comprehensive analysis of risk factors and metabolic profiling in preclinical atherosclerosis: a cross-sectional study.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to explore the factors influencing preclinical atherosclerosis (PCA) and provide evidence-based recommendations for its prevention. Non-targeted metabolomics technology was utilized to identify potential metabolic biomarkers associated with PCA. Materials and Methods: Data on general conditions, risk factors, and metabolic biochemical test results were collected from both the PCA group patients and the control group people. Blood plasma metabolites were analyzed using LC-MS/MS, which is a powerful technique that couples the separation power of liquid chromatography (LC) with the highly sensitive and specific detection of tandem mass spectrometry (MS/MS), making it indispensable for the comprehensive and accurate metabolic profiling required in preclinical atherosclerosis studies. Metabolites were annotated using the HMDB and LIPIDMaps databases, and differential metabolite pathways were enriched using the KEGG database. Results: Significant differences were observed between the two groups in terms of BMI, diet habits, smoking, physical activity, hypertension, and diabetes. Multivariate analysis identified smoking, high-salt diet, hypertension, and diabetes as significant risk factors for PCA. Biochemical blood tests revealed significantly elevated levels of triglycerides, LDL-C, GLU, and UA in the PCA group compared to the control group. Metabolomic analysis identified 105 differential metabolites in positive ion mode (29 upregulated and 76 downregulated) and 105 differential metabolites in negative ion mode (39 upregulated and 66 downregulated). The primary metabolic differences between the groups were related to lipid metabolism, inflammation-mediated processes, and amino acid metabolism. Conclusion: The incidence of PCA is influenced by smoking, unhealthy diet habits, hypertension, and diabetes. PCA patients frequently exhibit abnormalities in lipid metabolism, glucose metabolism, and purine metabolism. Metabolomic studies indicate that the metabolic differences in PCA primarily involve lipid metabolism, energy metabolism, and amino acid metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.